<DOC>
	<DOCNO>NCT00043186</DOCNO>
	<brief_summary>To determine effect denosumab treatment compare placebo 12 month bone mineral density ( BMD ) lumbar spine postmenopausal woman low BMD . The clinical hypothesis denosumab subcutaneous injection administer every 3 6 month 12 month significantly increase lumbar spine bone mineral density well tolerate .</brief_summary>
	<brief_title>Determine Efficacy , Safety Tolerability Denosumab ( AMG 162 ) Treatment Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Inclusion Criteria woman 80 year age date randomization ≥ 1 year postmenopausal date randomization ambulatory ≤ 60 year age , would require bilateral oophorectomy , serum follicle stimulate hormone ( FSH ) &gt; 50 mU/mL serum estradiol &lt; 20 pg/mL low BMD ( BMD Tscore ≤ 1.8 1 follow site : lumbar spine , femoral neck , total hip ; BMD Tscores must &lt; 4.0 lumbar spine 3.5 femoral neck total hip ) studyspecific procedure , include screen dual Xray absorptiometry ( DXA ) scan , give inform consent participation study . Exclusion Criteria fluoride treatment osteoporosis within 2 year enrollment date bisphosphonate use within 12 month enrollment date administration follow medication within 6 month enrollment date tibolone Parathyroid hormone ( PTH ) ( derivative ) systemic glucocorticosteroids ( &gt; 5 mg oral prednisone equivalent per day &gt; 10 day ) inhale corticosteroid ( &gt; 2000 μg per day &gt; 10 day ) anabolic steroid testosterone administration follow medication within 3 month enrollment date systemic hormone replacement therapy selective estrogen receptor modulators calcitonin calcitriol current hyper hypothyroidism ( allow stable thyroid replacement therapy thyroidstimulating hormone within normal range ) current hyper hypoparathyroidism albuminadjusted serum calcium &lt; 8.5 mg/dL ( &lt; 2.125 mol/L ) osteomalacia rheumatoid arthritis Paget 's disease malignancy within 5 year enrollment ( except cervical carcinoma situ basal cell carcinoma , acceptable ) renal disease ; ie , creatinine clearance ≤ 35 mL/min bone disease , osteoporosis , could interfere interpretation finding ( eg , osteogenesis imperfecta osteopetrosis ) malabsorption syndrome weight , height , girth could preclude accurate DXA measurement &lt; 2 lumbar vertebra ( L1 L4 ) evaluable DXA recent long bone fracture ( within 6 month ) osteoporoticrelated fracture ( ie , crush wedge vertebral fracture hip fracture ) know suspect occur within 2 year randomization &gt; 1 single , grade 1 vertebral fracture currently enrol participate within previous 30 day investigational device drug trial ( ) ( For trial , may allow discussion write approval Amgen . ) know sensitivity mammalianderived drug preparation ( eg , Herceptin® ) organic psychiatric disorder , serum chemistry , hematology , opinion investigator , could prevent subject complete study interfere interpretation study result selfreported alcohol drug abuse within previous 12 month disorder compromise ability give truly informed consent participation study previous administration denosumab know sensitivity contraindication alendronate know sensitivity contraindication tetracycline derivative ( subject biopsy substudy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>bone loss</keyword>
	<keyword>osteoporosis</keyword>
</DOC>